argenx SE (ARGX) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$921.63

From 52W high−12.04%

Volume645794.00

Market cap$58.57B

P/E (TTM)44.1x

P/S (TTM)14.1x

Div yield—

Key dataNov 4, 2026

Open

$921.63

From 52W high

−12.04%

Volume

645794.00

Market cap

$58.57B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

44.1x

RSI (14)

54.9

MomentumView details →

1D Return

+3.36%

YTD Return

+8.47%

SummaryUpdated Sep 1, 2026

argenx SE (NASDAQ:ARGX) is a Dutch biotechnology company founded in 2008 and headquartered in Amsterdam, Netherlands. The company went public on NASDAQ in May 2017. argenx has evolved from a research-stage biotechnology company into a commercial-stage biopharmaceutical company with its flagship product VYVGART achieving significant commercial success. The company specializes in developing antibody-based therapies for autoimmune diseases, with a particular focus on conditions affecting the neuromuscular system. argenx has established itself as a leader in targeting the neonatal Fc receptor (FcRn) pathway, a novel mechanism for treating antibody-mediated autoimmune diseases.

Ask drillr about argenx SE →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

44.1x

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

14.1x

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

89.15%

Net Margin

31.11%

EBITDA Margin

31.56%

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+116.24%

EPS CAGR 3Y

+51.87%

EBITDA YoY

—

MomentumView details →

1D Return

+3.36%

YTD Return

+8.47%

1Y Return

+9.60%

RSI (14)

54.9

vs 50D SMA

−2.54%

vs 200D SMA

+6.56%

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

$7.80

EPS Surprise

4.84%

Beats (12Q)

6/12

Next Q EPS Est

—

Avg Surprise (4Q)

9.61%

Rev Surprise

70.65%

Financials snapshotView financials →

Revenue (TTM)

8.69B

Net Income (TTM)

2.64B

Op. CF (TTM)

—

Next earningsFeb 25, 2027 →

Latest newsMore news →

ARGENX SE announced that it will host a conference call and audio webcast on October 22, 2026, to discuss its third-quarter financial results and provide a business update.21d ago

ARGENX SE shares fell 12%.27d ago

Similar companies

Amicogen, Inc.092040.KQ 荣昌生物688331.SH Pharmaron Beijing Co., Ltd.03759.HK Encell Co. Ltd.456070.KQ Akeso, Inc.09926.HK Genscript Biotech Corporation01548.HK Find similar companies →

Latest newsMore news →

ARGENX SE announced that it will host a conference call and audio webcast on October 22, 2026, to discuss its third-quarter financial results and provide a business update.21d ago ARGENX SE shares fell 12%.27d ago SueWallSt notified investors of a pending investigation into ARGENX SE.27d ago